Screener
Prime Medicine PRME Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue — related party | 7,934 | 7,824 |
| Operating lease liability | 8,972 | 8,137 |
| Total current liabilities | 31,692 | 37,448 |
| Deferred revenue, net of current — related party | 56,033 | 58,127 |
| Operating lease liability, net of current | 103,506 | 108,290 |
| Research and development funding liability | 18,000 | 18,000 |
| Total liabilities | 209,231 | 221,865 |
| Commitments and contingencies |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's contract liabilities?
- Prime Medicine (PRME) reported contract liabilities of $56.03M in Q2 2026.
- How has Prime Medicine's contract liabilities changed year-over-year?
- Prime Medicine's contract liabilities decreased by 5.9% year-over-year, from $59.56M to $56.03M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Prime Medicine's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude